{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Wen K"],"funding":["NIBIB NIH HHS","NIAID NIH HHS","NCI NIH HHS","NIGMS NIH HHS"],"pagination":["115842"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10935567"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["246"],"pubmed_abstract":["Therapeutic antibodies that block viral entry have already proven to be important, first line drugs for treatments of viral infections. In the case of SARS-CoV-2, combinations of multiple therapeutic antibodies may need to be rapidly identified and formulated in a way that blocks each new, predominant variant of the virus. For efficient introduction of any new antibody combination into patients, it is important to be able to monitor patient-specific pharmacokinetics of individual antibodies, which would include the time course of their specific capacity to block the viral spike proteins. Here, we present three examples of microfluidic-based rapid isolation of companion reagents useful for establishing combination antibody therapies. These reagents are specific three-dimensional imprints of variable regions of individual human monoclonal antibodies against the -spike protein of SARS-CoV-2 virus in the form of oligonucleotide-based ligands (aptamers). We implement these anti-idiotypic aptamers as bioreceptors in graphene-based field-effect transistor sensors to accomplish label free, rapid, and sensitive detection of matching antibodies within minutes. Through this work we have demonstrated the general applicability of anti-idiotype aptamers as capture reagents in quantification of active forms of monoclonal antibodies in complex biological mixtures."],"journal":["Biosensors & bioelectronics"],"pubmed_title":["Rapid isolation of anti-idiotype aptamers for quantification of human monoclonal antibodies against SARS-CoV-2 spike protein."],"pmcid":["PMC10935567"],"funding_grant_id":["R21 CA261775","R01 EB032910","U19 AI067773","R01 GM138843"],"pubmed_authors":["Taylor SK","Kalantarov G","Wen K","Lin Q","Rudchenko SA","Tong L","Stojanovic MN","Dai W","Trakht I","Wei J","Meng X"],"additional_accession":[]},"is_claimable":false,"name":"Rapid isolation of anti-idiotype aptamers for quantification of human monoclonal antibodies against SARS-CoV-2 spike protein.","description":"Therapeutic antibodies that block viral entry have already proven to be important, first line drugs for treatments of viral infections. In the case of SARS-CoV-2, combinations of multiple therapeutic antibodies may need to be rapidly identified and formulated in a way that blocks each new, predominant variant of the virus. For efficient introduction of any new antibody combination into patients, it is important to be able to monitor patient-specific pharmacokinetics of individual antibodies, which would include the time course of their specific capacity to block the viral spike proteins. Here, we present three examples of microfluidic-based rapid isolation of companion reagents useful for establishing combination antibody therapies. These reagents are specific three-dimensional imprints of variable regions of individual human monoclonal antibodies against the -spike protein of SARS-CoV-2 virus in the form of oligonucleotide-based ligands (aptamers). We implement these anti-idiotypic aptamers as bioreceptors in graphene-based field-effect transistor sensors to accomplish label free, rapid, and sensitive detection of matching antibodies within minutes. Through this work we have demonstrated the general applicability of anti-idiotype aptamers as capture reagents in quantification of active forms of monoclonal antibodies in complex biological mixtures.","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Feb","modification":"2025-04-04T01:24:18.26Z","creation":"2025-04-04T01:24:18.26Z"},"accession":"S-EPMC10935567","cross_references":{"pubmed":["38042051"],"doi":["10.1016/j.bios.2023.115842"]}}